Bionano Genomics Reaffirms 2026 Revenue Guidance and Targets EBITDA Neutrality by 2027
Bionano Genomics (BNGO) reported a strong third quarter, driven by the increasing global adoption of its optical genome mapping (OGM) technology. Management expressed confidence in the company's long-term financial trajectory during their recent earnings call. The company has reiterated its revenue guidance for 2026, projecting between $31 million and $33 million. Furthermore, Bionano is working toward a strategic goal of achieving adjusted EBITDA neutrality by the end of 2027 as it scales its operations.
Topics: earnings optical genome mapping quarterly results
Read the full article at Seeking Alpha
Part of the story FreightCar America Reaffirms 2026 EBITDA Guidance Amid Rising Aftermarket Revenue (3 articles)